Evidence map›Paper›PMID 24434434›Full record

ArticleBritish journal of cancer2014

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

T E Hutson, R M Bukowski, B I Rini, M E Gore, J M Larkin, R A Figlin, C H Barrios, B Escudier, X Lin, K Fly and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. Targeted Therapies in Older Adults With Solid Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Toxicity of Cancer Therapies in Older Patients.Current oncology reports · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

T E HutsonBaylor Sammons Cancer Center-Texas Oncology, PA, Dallas, TX, USA.
R M BukowskiCleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
B I RiniCleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
M E GoreRoyal Marsden Hospital NHS Trust, London, UK.
J M LarkinRoyal Marsden Hospital NHS Trust, London, UK.
R A FiglinSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
C H BarriosPUCRS School of Medicine, Porto Alegre, Brazil.
B EscudierInstitut Gustave Roussy, Villejuif, France.
X LinPfizer Oncology, La Jolla, CA, USA.
K FlyPfizer Oncology, Groton, CT, USA.
B MartellPfizer Oncology, New York, NY, USA.
E MatczakPfizer Oncology, New York, NY, USA.
R J MotzerMemorial Sloan-Kettering Cancer Center, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe retrospectively analyzed sunitinib outcome as a function of age in metastatic renal cell carcinoma (mRCC) patients.

methodsData were pooled from 1059 patients in six trials. Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) were compared by log-rank test between patients aged <70 (n=857; 81%) and ≥70 (n=202; 19%) years.

resultsIn first-line patients, median PFS was comparable in younger and older patients, 9.9 vs 11.0 months, respectively (HR, 0.89; 95% CI: 0.73-1.09; P=0.2629), as was median OS, 23.6 vs 25.6 months (HR, 0.93; 95% CI: 0.74-1.18; P=0.5442). Similarly, in cytokine-refractory patients, median PFS was 8.1 vs 8.4 months (HR, 0.79; 95% CI: 0.49-1.28; P=0.3350), while median OS was 20.2 vs 15.8 months (HR, 1.14; 95% CI: 0.73-1.79; P=0.5657). Some treatment-emergent adverse events were significantly less common in younger vs older patients, including fatigue (60% vs 69%), cough (20% vs 29%), peripheral edema (17% vs 27%), anemia (18% vs 25%), decreased appetite (13% vs 29%), and thrombocytopenia (16% vs 25%; all P<0.05). Hand-foot syndrome was more common in younger patients (32% vs 24%).

conclusionsAdvanced age should not be a deterrent to sunitinib therapy and elderly patients may achieve additional clinical benefit.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Renal CellClinical Trials, Phase III as TopicDisease-Free SurvivalFemaleHumansIndolesKidney NeoplasmsMaleMiddle AgedProspective StudiesPyrrolesRandomized Controlled Trials as TopicRetrospective StudiesIndolesPyrrolesSunitinib

Identifiers

PMID24434434
PMCPMC3950861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.